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The modern drug discovery process has largely focused its attention in the so-called magic bullets, single chemical
entities that exhibit high selectivity and potency for a particular target. This approach was based on the assumption
that the deregulation of a protein was causally linked to a disease state, and the pharmacological intervention
through inhibition of the deregulated target was able to restore normal cell function. However, the use of cocktails
or multicomponent drugs to address several targets simultaneously is also popular to treat multifactorial diseases
such as cancer and neurological disorders. We review the state of the art with such combinations that have an
epigenetic target as one of their mechanisms of action. Epigenetic drug discovery is a rapidly advancing field, and
drugs targeting epigenetic enzymes are in the clinic for the treatment of hematological cancers. Approved and
experimental epigenetic drugs are undergoing clinical trials in combination with other therapeutic agents via fused
or linked pharmacophores in order to benefit from synergistic effects of polypharmacology. In addition, ligands are
being discovered which, as single chemical entities, are able to modulate multiple epigenetic targets simultaneously
(multitarget epigenetic drugs). These multiple ligands should in principle have a lower risk of drug-drug interactions
and drug resistance compared to cocktails or multicomponent drugs. This new generation may rival the so-called
magic bullets in the treatment of diseases that arise as a consequence of the deregulation of multiple signaling
pathways provided the challenge of optimization of the activities shown by the pharmacophores with the different
targets is addressed.
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Principles of polypharmacology
Notwithstanding the success of combination therapy,
the use of a single drug that modulates several targets
might be therapeutically advantageous over the use of
drugs in combination. In cancer, the design and synthesis
of new molecules that simultaneously modulate multiple
biochemically distinct oncogenic targets is of current
interest. Polypharmacology refers to the ability of drugs to
interact simultaneously and specifically with multiple
targets (multitarget drugs). Although polypharmacology
might be associated with compound promiscuity, it should* Correspondence: qolera@uvigo.es; A.Ganesan@uea.ac.uk
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adverse reactions [1].
Among the advantages of multitarget drugs vs drug
combinations are the more predictable pharmacokinetic
(PK) and pharmacodynamic (PD) relationship of the
components of a single medicine, the possibility that
one motif might improve the bioavailability of the sec-
ond entity, the greater efficacy against advanced-stage
diseases, the lower toxicities, the simultaneous presence
of the chemical entities in multiple tissues, and the im-
proved patient compliance [2]. To benefit from those
effects, it is required that the multitarget drug exhibit
balanced in vitro and in vivo activities to match potency
for the corresponding targets, as well as optimized PK
and safety profiles. A combination of drugs faces thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
de Lera and Ganesan Clinical Epigenetics  (2016) 8:105 Page 2 of 21problem of the different solubilities that may modify
the bloodstream uptake, which requires fine-tuning the
formulation in order to ensure the required blood level
of each drug. In addition, the regulatory requirements
are more complex when the agents are used in combin-
ation, since the safety profile of each drug needs to be
demonstrated before clinical trials, and this can be fur-
ther delayed due to regulatory and IP issues, in particu-
lar if the two drugs are being developed by different
companies [1].
Efforts are underway to use chemoinformatics to help
understand drug effects from a signal transduction
network perspective [3], to confidently predict new
molecular targets for known drugs, and to explain poly-
pharmacology. Another current trend in therapy is drug
repurposing or the re-discovery of a new therapeutic
area for a drug used traditionally to treat a given path-
ology, either through the ability to modulate an add-
itional target or by the involvement of the primary
target in multiple pathologies. Examples include the
use of the anti-angina drug sildenafil to treat sexual
disfunction or the infamous sedative thalidomide as
therapy for multiple myeloma. Indeed, the polypharma-
cology of current drugs has been studied using a statis-
tical ligand-based approach [4]. This study, aimed to
discover chemical similarities between drugs and ligand
sets, has revealed unanticipated promiscuities but also
previously unreported polypharmacologies. The screen-
ing study of the 3665 FDA-approved and investigational
drugs was conducted using databases containing the
chemical structures of hundreds of thousands of biologic-
ally active compounds for which the binding characteris-
tics to a panel of 1400 target proteins were known [4]. A
massive network of interactions (nearly 7000 of them with
high probability) for the studied compounds with off-
targets were predicted, which indicates that polypharma-
cology is, perhaps unintentionally, a feature intrinsic to
the therapeutic efficacies of drugs.
Multikinase inhibitors, for example, initially considered
to be highly specific for one of the 518 kinases of the
kinome, have proven successful in treating previously
refractory cancers, perhaps as a result of simultaneous
inhibition of multiple kinases. As an example, sunitinib, a
promising drug for the treatment of anaplastic thyroid
cancer, inhibits 79 kinases with KD < 10 μM. Therefore,
the success of (multi)kinase inhibitors in treating cancer is
a consequence of the modulation of multiple signaling
pathways that support cancer cell proliferation, apoptosis,
angiogenesis and recruitment of surrounding tissues.
Also, in infectious diseases, current drugs show off-target
effects. This is the case with the HIV protease inhibitor
nelfinavir, which has been found to also inhibit the prolifer-
ation of cancer cells due to a weak modulation of multiple
kinases.Polypharmacology is prevalent in the area of CNS
diseases. The activity of drugs acting on the CNS is often
mediated by G protein-coupled receptors (GPCRs), a
group of receptors that are also implicated in multiple
therapeutic areas and share structural and functional
similarities that makes selectivity a very difficult issue.
For example, the use of atypical antipsychotic clozapine
is associated with undesired side effects, such as diabetes
and seizures, which may be due to its broad range of
targets, among them different isoforms of the serotonin,
dopamine, muscarinic, and adrenergic receptors, members
of the GPCR superfamily. On the other hand, a single
drug exhibiting polypharmacology for more than one tar-
get of the same disease could exhibit synergistic effects.
This is the case of ladostigil, an inhibitor of acetylcholine
esterase (AChE) and the brain monoamine oxidases
(MAO) A and B, which has shown efficacy in models of
Alzheimer’s disease.
Multitarget drugs exhibiting polypharmacology due to
their ability to modulate as single chemical entities mul-
tiple targets simultaneously are also termed multiple
ligands [5] and hybrid molecules [6]. These molecules
should not be considered as pro-drugs, which are those
designed to correct the pharmacokinetic and pharmaco-
dynamic profiles of a valuable lead. For example, the
hydroxamic acid functionality of the approved histone
deacetylase inhibitor (HDACi) vorinostat (also known as
SAHA, suberoylanilide hydroxamic acid, 1) was cova-
lently bound to a thiol-sensitive group in the design of a
dual-mode HDAC prodrug (SAHA-TAP, 2) in order to
facilitate the delivery of the drug, which itself has poor
pharmacokinetics [7]. Selective activation by glutathione
3, which is present at higher concentrations in cancer
cells (1 mM) than in the intracellular compartment
(1 μM), would release the hydroxamate of 1 upon conju-
gate addition to the quinone giving 4 (Scheme 1).
Hybrid molecules [6], in contrast to pro-drugs, contain
two (or more than two) domains with different bio-
logical functions and dual activities that ideally act as
distinct pharmacophores, although not necessarily on
the same biological target. Thus, multiple ligands usually
consist of the combination of pharmacophores of select-
ive ligands (either already known drugs or candidates).
From the point of view of the medicinal chemist, phar-
macophores that are similar and share common sub-
structures, usually hydrophobic or basic ring systems,
can be synthetically fused or merged (see examples in
next section). Alternatively, if pharmacophores are dis-
similar, they can be joined as conjugates with cleavable
or non-cleavable linkers, although this strategy often
leads to structures of high molecular weight (MW) and
lipophilicity [5].
When both pharmacophores are connected by a linker
that is labile or can be easily cleaved in vivo, they are
Scheme 1 Examples of pro-drugs and mutual pro-drugs containing an HDACi and release mechanisms. In brackets, the structures of the
corresponding HDACis
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another pharmacologically active compound instead of
some inert molecule as carrier. Being released simultan-
eously inside the cancer cells, they might act synergistic-
ally and affect distinctive cellular targets, in contrast to
the simultaneous administration of two individual syner-
gistic agents, which are usually transported to the site of
action with different efficiencies.
Examples of hybrid anticancer molecules containing
an epi-drug and another antitumor agent connected via
a linker are shown in Scheme 1. The scaffold of the
HDACi dacinostat (LAQ-824, compound 7; an early
candidate that was further improved as panobinostat 8)
and a tubulin binder (thiocolchicine 9 and paclitaxel 10)
were connected via a disulfide bond as in 5 and 6 [8].
Glutathione 3 would release the thiolates via disulfide
exchange reactions, which in turn would produce the
thiolactones to free the second component.
Mutual pro-drugs of all-trans-retinoic acid (ATRA)
and several HDACis (butyric acid 13, tacedinaline 15and entinostat 17) have been engineered via glycine
acyloxyalkyl carbamate linker (which would be presum-
ably cleaved by esterases, compounds 11a-12 and 11a-14)
or through a benzyl ester linker (which would be presum-
ably released through a 1,6-elimination reaction, com-
pounds 11b-12 and 11b-16 and 11b-14) [9]. The last
series of mutual pro-drugs showed potent inhibition of
the growth of several hormone-insensitive/drug resistant
breast cancer cell lines and the hormone-insensitive PC-3
prostate cancer cell line [10].
Still, the development of multitarget drugs from leads
is more complex than that of single drugs. Drug-like
molecular properties for multiple pharmacological activ-
ities must be optimized and unintended interactions
with additional targets minimized. Moreover, balancing
the pharmacological activities is another complication,
as often the optimal ratio is not 1:1. For example, although
the hybrid compounds 5 and 6 were able to retain antimi-
totic and proapoptotic activity, the potency of the con-
struct was lower than anticipated [8].
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molecules can be classified in three different categories:
(a) both entities interact with the same target (“double
sword” molecules); (b) both entities independently inter-
act with two different and nonrelated targets; (c) both
entities interact simultaneously with two related targets
at the same time [6].
Main text
Challenges for rational epigenetic drug
polypharmacology
The new paradigm of single chemical entities that
antagonize multiple biochemically distinct targets to over-
come conventional single-target therapeutics is being pur-
sued in the epigenetic field, in particular for the treatment
of cancer [11, 12]. The challenge in this field is the design
of small molecules that have the property to modulate at
the same time several of the epigenetic targets with con-
trasting or totally unrelated mechanism of action. Promis-
cuity, traditionally considered an undesired property of
drugs, might turn out to be advantageous also in epigenet-
ics and the polypharmacology of these epi-drugs a feature
intrinsic to their therapeutic efficacies.
In principle, since some of the epigenetic enzymes such
as sirtuins (SIRTs), protein arginine methyltransferases
(PRMTs), DNA methyltransferases (DNMTs), and lysine
methyltransferases (KMTs) use the same cofactor or cofac-
tors containing adenosine, modulators of several of these
enzymes that bind to the corresponding adenosine pockets
can be designed, and moreover, these might also cross-
react with related receptors such as kinases. Likewise, the
metalloenzymes HDACs and Jumonji lysine demethylases
(KDMs) can be subjected to simultaneous inhibition with
metal-chelating containing compounds. However, these
simple assumptions cannot be extrapolated to the differentScheme 2 Mechanism of acetyl transfer in the ternary complex containingprotein families. For example, the S-adenosyl methionine
(SAM) binding site of lysine methyltransferases is more ex-
tended than that of other enzymes using the same cofactor
such as DNMTs. Both the SAM cofactor and the substrate
of KMTs access the protein from opposite faces in domains
linked through a narrow hydrophobic channel. In addition,
the SAM cofactor adopts different conformations in the
domains of KMTs compared to PRMTs although both
enzymes transfer a methyl group to protein side-chains.
Even more challenging is the inhibition of epigenetic
enzymes with unrelated mechanistic principles. To get a
glimpse of the difficulties expected in the rational design
of multiple epigenetic ligands, a brief description of the
reaction mechanisms for the most common epigenetic
enzymes follows.
Writers/erasers of acetyl groups
The acetylation status of lysine ε-amino residues in histones
is under the control of the opposing activities of histone
deacetylases and histone acetyltransferases (HDACs and
HATs, respectively). In addition to the regulation of chro-
matin function and structure, acetylation has a broad regu-
latory role in many biological processes (cell cycle, splicing,
nuclear transport, actin nucleation [13], cellular metabolism
[14, 15], etc.) beyond chromatin remodeling. These effects
might be due to the modulation by the acetylation/deacety-
lation mechanistic switch of the activities of a large number
(more than 1700) of histones and non-histone proteins,
among them tubulin, p53, Hsp90, and NFYA (nuclear tran-
scription factor Y subunit alpha) [16].
Mechanism(s) of acetyl transfer to lysine residues
HATs catalyze the transfer of acetyl groups to lysine resi-
dues using acetyl-CoA as donor. Scheme 2 depicts the
transfer of the acetyl group to the lysine ε-amino residuesthe HAT, acetyl-CoA (insert), and a fragment of H3 [17]
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bound to a hydrophobic pocket located close to the acetyl
group of the acetyl-CoA binding site, which is one of the
mechanisms proposed based on crystal structures [17].Mechanism(s) of acetyl-lysine hydrolysis by Zn2
+-dependent deacetylases The histone deacetylase fam-
ily is composed of 18 members [18], which are divided
into two groups depending on their mechanism of ac-
tion: the classical Zn2+-dependent enzymes (HDAC1-11)
and the NAD+ cofactor-dependent enzymes (SIRT1-7).
The metalloprotein HDACs can be further classified into
three groups: class I (HDAC1–3 and 8); class II
(HDAC4–7 and 9–10), which may be divided into two
subclasses, class IIa (HDACs 4, 5, 7, and 9) and class IIb
(HDACs 6 and 10) on the basis of evolutionary relation-
ships; and class IV, composed of HDAC11. Differences
between class I and II HDACs are primarily noted in
their size (with class II being from two to three times
larger), their cellular localization, the conservation of
sequence motifs in their catalytic domains, the identity
of the protein-protein interaction complexes, and their
tissue distribution.
Based on the ligand-bound crystal structures, the mech-
anism of deacetylation (Scheme 3) was recognized to in-
volve the activation of the acetamide carbonyl group by
the Zn2+ ion and its hydrolysis with formation of a tetra-
hedral intermediate facilitated by a “charge-relay” system.
Several variants of the deacetylation mechanism have been
proposed [19–22]. The most recent computations support
the involvement of two charge-relay systems, the recogni-
tion of the H142/D176 dyad as the general base of the
reaction, the stabilization of the intermediate by Y306,
and the inhibitory effect of K+ (Scheme 3).
HDAC inhibitors [23] emulate the native acetylated
lysine using a Zn2+-chelating “head group” attached via a
connector of variable length and functionality to a cap
region. The Zn2+-chelating “head groups” reported in
HDACis includes virtually all functionalities known to
bind transition metal ions (hydroxamic acids, thiols, mer-
captoamides, trifluoromethylketones…), which most likely
compete with the natural substrate after binding siteScheme 3 Simplified mechanism for HDAC-8 catalyzed deacetylation reactoccupancy [23]. For general inhibition by hydroxamic
acids, a spontaneous proton transfer to an active site histi-
dine upon binding of the inhibitor to the zinc was sup-
ported by recent computations; accordingly, for thiol-
containing inhibitors (or precursors such as disufides or
thioesters), the thiolate appears to be the active species
[22].
Mechanism(s) of acetylated lysine deacetylation by
sirtuins Catalytic mechanisms of nucleophilic substitu-
tion SN1-type [24, 25] or SN2-type [26–28] deacetyla-
tion by NAD+-dependent class III deacetylases or
sirtuins [29] have been proposed with formation of an
O-alkylamidate intermediate as shown in Scheme 4. A
highly dissociative and concerted displacement of nico-
tinamide has been proposed as first step of the mechanism
of deacetylation. The transition state shows a significant
oxocarbenium ion character, but the cleavage appears to
be facilitated by the nucleophilic assistance of the acety-
lated lysine, as shown by dynamics simulations [30].
Writers/erasers of methyl groups
Mechanism of methyl transfer catalyzed by DNMTs
A mechanistic proposal for the DNA methylation at the
cytosine C5 position in CpG nucleotide islands catalyzed
by DNMT is shown in Scheme 5. The formation of a
reactive enamine intermediate by the addition of a cyst-
eine residue of the DNMT binding pocket to cytosine
C6 position following base-flipping [31, 32], assisted by
the protonation at C3 by a glutamic acid, is followed by
the transfer of the methyl group of cofactor SAM to and
a β-elimination on the 5-methyl-6-Cys-S-5,6-dihydrocy-
tosine intermediate.
Mechanism of methyl transfer catalyzed by HMTs
The mechanism of methyltransferases of arginine and
lysine residues of histones [33] is a classical nucleo-
philic substitution reaction of the methyl group donor
SAM (Scheme 6) by the partially deprotonated terminal
amino group of the basic amino acids, thus releasing S-
adenosylhomocysteine (SAH) from the cofactor [34].ions [22]
Scheme 4 Mechanism of deacetylation of acetylated lysine catalyzed by sirtuins [24, 25, 30]. Insert is the structure of the cofactor NAD+
de Lera and Ganesan Clinical Epigenetics  (2016) 8:105 Page 6 of 21Computational studies of SET7/9, a monomethyltrans-
ferase (H3K4), revealed an in-line SN2 mechanism via a
transition state of 70 % dissociative character [35].
More recent computations based on kinetic isotope
effects are consistent with a SN2 mechanism involving
the methyl transfer as the first irreversible step, with a
transition state where the leaving group departure is
retarded (2.5 Å) relative to the bond formation (2.1 Å)
by the attacking nucleophile [36].
Similarly, the addition of methyl groups to arginine res-
idues catalyzed by PRMTs uses SAM as cofactor but
can produce mono- and/or dimethylarginine derivatives,
the latter as the symmetric or non-symmetric isomers
(Scheme 6) [37].
Nature uses two unrelated mechanisms for the re-
moval of methyl groups from the methylated lysine and
arginine residues [38, 39], each catalyzed by different
demethylase enzymes [40]: (a) lysine specific demethylaseScheme 5 Mechanism of cytosine methylation at C5 catalyzed by DNMT, w1 (LSD1/KDM1) and (b) Jumonji JmjC domain-containing
demethylases (JHDMs).
The demethylation mechanism proposed for the LSD1/
KDM1 demethylase starts with the oxidation of a proton-
ated mono- or dimethylated lysine by oxidative cleavage
of the α-CH bond of the substrate to form an iminium ion
intermediate, with concomitant reduction of the cofactor
flavin adenine dinucleotide (FAD) to FADH2, which is
then reoxidized by molecular oxygen producing H2O2
(Scheme 7). The iminium ion intermediate is then enzy-
matically hydrolyzed to produce a carbinolamine, which
releases formaldehyde and the demethylated lysine resi-
due. The precise mechanism of imine formation is subject
to debate, and either hydride or single electron transfer
has been proposed for this step [41–43].
The oxidative demethylation reaction catalyzed by the
JmjC family, similar to those catalyzed by dioxygenases
that use Fe(II), takes place in a ternary complexith SAM as electrophile
Scheme 6 (top) Mechanism of methylation of histone lysine residues catalyzed by KMTs [35, 37] and (bottom) of arginine residues catalyzed by PRMTs [37]
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methylated lysine as shown in Scheme 8 [44–46]. First,
the α-ketoglutarate complexed Fe(II) transfers an elec-
tron to the coordinated oxygen, giving rise to a perox-
ide anion (superoxide radical) and Fe(III). Nucleophilic
attack of the anion to the carbonyl group (C2) of α-
ketoglutarate produces an Fe(IV) bicyclic peroxyhemi-
ketal and the intermediate undergoes decarboxylation
to succinate. A highly unstable oxo-Fe(IV) intermediate
is generated, and the oxoferryl group abstracts a hydro-
gen atom from the methyl group of N-methylated
lysine, forming a Fe(III) hydroxide. Then, the radical re-
combination generates a carbinolamine that releases
formaldehyde and the demethylated peptide.Readers
The bromodomain and extra terminal domain (BET) fam-
ily of tandem bromodomain-containing proteins (BRD2,
BRD3, BRD4, and BRDT) exhibit a wide variety of bio-
logical effects and are the first readers to be targeted in
epigenetic drug discovery. They are promising agents for
the treatment of a spectrum of human diseases, ranging
from cancer and inflammation to viral infections [47–49].
The binding of small molecules to the acetyl-lysine pocket
(KAc) can block the recognition of their acetylated partner
proteins via protein-protein interactions. Despite their
overall structural similarity [47–49], subtle differences
exist between the bromodomain structures and their func-
tions that can account for their specificity.
Scheme 7 Mechanism of lysine demethylation catalyzed by LSD1 (BHC110, KDM1A)
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The first drugs targeting epigenetics in fact predated a
clear understanding of such mechanisms at the mo-
lecular level and the identification of the proteins re-
sponsible. Instead, the early compounds were advanced
through the drug discovery process on the basis of
their phenotypic effects in cancer models without
knowledge of the precise targets.Scheme 8 Mechanism of N-methyl lysine demethylation by the JHDM en
demethylation of H3K9me2, H3K9me3, and H3K36me3The recognition that analogues of purine and pyrimi-
dine nucleosides might act as anti-metabolites that dirsupt
nucleic acid biosynthesis or function led to many such
molecules being investigated. At the Czech Academy of
Sciences, Piskala and Sorm synthesized 5-azacytidine (18)
and the corresponding deoxyribose analogue 19 and dem-
onstrated antileukemic activity in cells and AKR mice.
Clinical trials with 18 began in 1967 in Europe and inzymes. The numbering is that of JMJD2A/KDM4a, which catalyzes
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with the American National Cancer Institute. This was
however rejected due to an unacceptably high level of
toxicity. Interest in these nucleosides was rejuvenated due
to the 1980 publication by Jones identifying DNMTs as
their molecular target. Both 18 and 19 went back into
clinical trials for the treatment of myelodysplastic syn-
drome, a hematological stem cell disorder that frequently
progresses to acute myeloid leukemia, and were approved
by the FDA in 2004 and 2006, respectively [50]. The nu-
cleosides 18 and 19 are pro-drugs that enter the cell
through transporters and are metabolically converted to
the 5′-triphosphate of 19. The triphosphate is incorpo-
rated into DNA strands, recognized as a cytosine substrate
by DNMTs, and forms a covalent adduct with the enzyme
via addition of the active site Cys residue to C-6 of the
azapyrimidine heterocycle (see Scheme 5). The drugs are
thus irreversible DNMT inhibitors, but their lack of select-
ivity between DNMT isoforms may be one reason for the
high toxicity observed in settings other than myelodys-
plastic syndrome.
The first clinically approved inhibitors of zinc-dependent
HDACs, vorinostat (SAHA, 1) and romidepsin (20), were
similarly discovered on the basis of their antiproliferative
effects in cancer cells. Vorinostat evolved from DMSO as a
lead for the differentiation of murine leukemia cells while
romidepsin was identified in a screening campaign for
compounds that reverse the phenotype of ras-transformedFig. 1 Epi-drugs approved for therapy (1, 8, 18–22), other drugs with epig
clinical studiescells [51]. These compounds, like the other HDAC inhibi-
tors displayed in Fig. 1, reversibly occupy the enzyme active
site with the dominant interaction being coordination to
the zinc cation (see Scheme 3) [52]. The most popular
zinc-binding motif in synthetic HDAC inhibitors is a
hydroxamic acid as in vorinostat and more recently
approved agents panobinostat 8 and belinostat 21. Another
widely used zinc-binding group in medicinal chemistry
efforts towards HDAC inhibitors is the benzamide as in
chidamide 22 recently approved in China and entinostat
17 currently in clinical trials. Meanwhile, sodium butyrate
23 was in fact reported by several groups in 1977 and 1978
to increase the acetylation levels of histones through the
inhibition of deacetylation. This led to the repurposing of
sodium valproate 24, an antiepileptic drug that primarily
works through its action on voltage-gated sodium chan-
nels, as an HDAC inhibitor. At this point of time, such
short chain carboxylic acids have yet to receive clinical
approval as anticancer agents and their level of
HDAC inhibition is modest compared to the hydroxa-
mic acids and benzamides. Compared to the other
clinical HDAC inhibitors, romidepsin 20 is unique in
that it is a natural product rather than of synthetic
origin. Furthermore, it is a disulfide prodrug that
undergoes reduction in vivo to release a free thiol
that acts as the zinc-binding group. Unlike vorinostat
that is a pan-HDAC inhibitor, romidepsin is selective
for class I isoforms.enetic activities (23, 24), and a candidate (17) undergoing advanced
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polypharmacology
Current clinical practice uses drug combination therap-
ies rather than single drugs [4] to treat patients with
complex diseases [53]. The first clinical success with
combination chemotherapy for childhood acute lympho-
blastic leukemia (ALL) consisted of the co-administration
of the anti-folate methothrexate, the tubulin-targeting
vincristine (a Vinca alkaloid), the antimetabolite 6-
mercaptopurine and the steroid prednisone. Either such a
drug cocktail containing two or more individual tablets to
combine therapeutic mechanisms or the co-formulation
of two or more agents in a single tablet are the traditional
modalities of drug combinations. The design of a drug
combination aims to simultaneously block disease-related
targets and is expected to ensure a more durable control
of the disease progression compared to single agents.
Therefore, the individual drugs should be active against
their own target and ideally elicit synergistic effects when
used in combination without increasing the toxicity and
reducing drug resistance. Mathematical models have been
recently developed that analyse the dynamics of pairs of
drugs in a weighted linear superposition in order to obtain
predictive drug effects (synergy, independence, antagon-
ism…) from their use as multidrug and multidose combi-
nations [54].
Following the trait mentioned above for the treat-
ment of ALL, numerous combination therapies have
been investigated for treating complex pathologies
such as cancer, parasitic diseases, and multiple scler-
osis that are polygenic in nature and result from the
deregulation of complex protein networks. New drugs
in the market, in particular those with a defined mech-
anism of action or target, are studied in combination
even before they are launched. For example, in cancer,
there are a large number of clinical studies that com-
bine the proteasome inhibitor bortezomib with other
drugs targeting not only the epigenome but also
Hsp90, kinases, farnesyltransferases, etc., for both solid
tumors and leukemias.
Post-genomic research over the last decade is shifting
the focus of rational combination modalities to what is
called “personalized medicine.” In the case of cancer, it
involves targeting pathogenic oncogene and non-oncogene
addictions, synthetic lethalities, and other vulnerabilities,
attacking complementary cancer hallmarks or distinct cell
populations with molecular targeted agents and using in
addition other therapeutic options such as cytotoxic
chemotherapy [55].
Despite the success of HDACis as single agents in the
treatment of hematological maligancies, the treatment of
patients with solid tumors has demonstrated limited
clinical benefit [56]. For example, vorinostat 1 failed as
monotherapy for the treatment of metastatic breastcancer in clinical trials [57]. This failure has prompted
the investigation of novel treatment combinations with
other cancer therapeutics, including kinase inhibitors,
DNA-damaging chemotherapeutic agents, radiotherapy,
hormonal therapies, and other epi-drugs (primarily DNA
methyltransferase inhibitors), for which a rationale has
been described [58].
In the case of tyrosine kinase inhibitors (TKIs), com-
bination and multitarget therapies, including epigenetic
drugs, are being developed since a large number of pa-
tients do not respond to single therapy or develop re-
sistance. The results are encouraging. Vorinostat 1 and
sorafenib 25 appear to interact in a synergistic fashion
to kill carcinoma cells by activating CD95 through gen-
eration of ROS due to induction of cytosolic Ca2+ that
elevates dihydroceramide levels [59]. Vorinostat 1 and
other antagonists of receptor tyrosine kinase induced
a synergistic induction of growth inhibition and apop-
tosis in the treatment of non-small cell lung cancer
(NSCLC) (NCT00251589) (NCT00503971). The HDACi
MPT0E028 45 (shown in Fig. 4 below) enhances erlotinib
(26)-induced cell death in epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKI)-resistant
NSCLC cells [60]. Combination of EGFR-TKIs with vori-
nostat 1 resulted in significantly decreased cell viability
through the activation of the apoptotic pathway and
caspase-independent autophagic cell death [61].
Combination of vorinostat 1 with second-generation
TKIs such as afatinib 27 or third-generation TKIs includ-
ing WZ4002 28 enhanced anti-tumor effect on xenografts
of H1975 cells in vivo. The combination of new gener-
ation EGFR-TKIs and vorinostat 1 may be a new strategy
to overcome the acquired resistance to EGFR-TKIs in
T790M mutant lung cancer [61].
Synergistic effects of vorinostat 1 or sodium butyrate
23 with imatinib 29, an ABL kinase inhibitor that can
kill Breakpoint cluster region—Abelson (BCR-ABL)
positive chronic myeloid leukemia (CML) cells, were
observed and shown to enhance apoptosis in BCR-ABL
expressing CML cells. The combination treatment was
also effective against imatinib-refractory CML. Both
wild-type BCR-ABL and the T315I mutant form of
BCR-ABL, which is resistant to imatinib, were equiva-
lently degraded following that combinatorial treatment
[62, 63].
Vascular endothelial growth factor (VEGF) and its re-
ceptor vascular endothelial growth factor receptor
(VEGFR)-2 or kinase insert domain receptor (KDR) are
key regulators of angiogenesis, which plays a key role in
the growth of solid tumors and contributes to the pro-
gression of cancer metastasis. A phase I study of vori-
nostat 1 and VEGFR inhibitor gefitinib 30 (Fig. 2) in
combination therapy has been approved for targeting
resistance by B cell chronic lymphocytic leukemia-
Fig. 2 Selection of TKIs used in combination therapies with epi-drugs
de Lera and Ganesan Clinical Epigenetics  (2016) 8:105 Page 11 of 21lymphoma-like 11 gene (BIM) polymorphysim in EGFR
mutant lung cancer (VICTORY-J) (NCT02151721).
HDACis have been shown to downregulate estrogen
receptor (ER) and androgen receptor (AR) mRNA in
receptor-positive breast and prostate cancer cells [64–66].
Current drug therapies include tamoxifen 32 and ralox-
ifene 33, competitive ER inhibitors that act as selective
estrogen receptor modulators (SERMs), and pure anti-
estrogens such as fulvestrant 34, which act as a select-
ive ER downregulator (SERDs). Raloxifene 33 is an
antagonist in all tissues, whereas tamoxifen 32 displays
partial agonistic activity in a tissue and gene specific
manner. In ER-negative cells, silenced ERs can be re-
expressed using HDACi, restoring sensitivity to tamoxi-
fen 32 [67]. HDACi increase the antitumor effects of
tamoxifen 32 in several ER-positive breast cancer cell
lines and breast tumors that are resistant to tamoxifen
(NCT00365599) (NCT01194427) (NCT02395627). Co-
treatment of breast cancer cells with HDACi and tamoxi-
fen 18 produced a synergistic effect with depletion of both
ER and progesterone receptor (PR), and this effect was ex-
clusive of HDAC2-selective inhibitors [64]. In phase II
clinical studies, the combination of vorinostat 1 andFig. 3 Selection of modulators of NRs used in combination therapies withtamoxifen 32 is well tolerated by patients with ER-positive
metastatic breast cancer progressing on endocrine therapy
and exhibits promising activity in reversing hormone re-
sistance. A 19 % objective response rate and a 40 % clinical
benefit rate were noted [68].
HDACi have shown antiestrogenic activity in human
MCF7 breast cancer cells. The effect of the HDACis
sodium butyrate 23 and vorinostat 1, alone and in com-
bination with 17β-estradiol (E2) 35 and the pure anti-
estrogen fulvestrant 34 was examined. HDACis were
found to antagonize the effect of E2 on the expression of
cell cycle proteins, cell growth, and transcription of ER-
dependent genes as a consequence of downregulation of
the expression of ERα and prevention of receptor phos-
phorylation [69]. Thus, the combination of anti-estrogens
with HDACi in clinical settings may improve efficacy
while reducing side effects (Fig. 3).
A phase I study of the histone deacetylase inhibitor
entinostat 17 in combination with 13-cis-retinoic acid
36 was carried out in patients with solid tumors, but no
tumor responses were seen [70].
Vorinostat 1 in combination with the proteasome
inhibitor bortezomib 38 (Fig. 4) resulted in synergisticepigenetic drugs
Fig. 4 Selection of epi-drugs and other drugs used in combination
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cell lines (NCT00574587) (NCT00258349) [71]. The
same combination was found to block tumor cell growth
in relapsed or refractory multiple myeloma (MM) pa-
tients (NCT00773747). The approval of panobinostat 8
for the treatment of MM patients was accelerated after
the promising activity exhibited by its combination with
bortezomib 38 and dexamethasone 39 (PANORAMA-1
phase III randomized clinical trial).
A phase I study has been initiated to evaluate the
safety and efficacy of oral panobinostat 8 in combination
with radiotherapy or chemoradiotherapy in patients with
inoperable stage III NSCLC [72].
The approved DNMTi are likewise undergoing clinical
studies in combination with other agents. Promising re-
sults have been obtained in the combination of DNMTi
decitabine 19 plus TIK dasatinib 31 in phase I/II clinical
studies in patients with CML (NCT1498445) [73].
Decitabine 19 combined with the DNA-damaging agents
carboplatin 40 is in phase II clinical trials in platinum-
resistant ovarian cancer (NCT00477386) [74].
The LSD1 inhibitor tranylcypromine (TCP, 41) com-
bined with all-trans-retinoic acid 37 (Fig. 3) is now in
clinical trials for the treatment of adult patients with
acute myeloid leukemia (AML) and myelodisplastic
syndrome (MDS) (NCT02273102) and patients with
relapsed or refractory AML (NCT02261779) in non-acute
promyelocytic leukemia (APL) AMLs when treatment
with all-trans-retinoic acid 37 is not effective.
The topoisomerase IIa (TopIIa) inhibitor etoposide
42 combined with the Enhancer of Zeste Homologous2 (EZH2) inhibitors 7-deazaneplanocin A (DZNep) 43
or GSK126 44 induces cell death in murine and human
prostate cancer cell lines and showed therapeutic efficacy
in vivo. Thus, the combination of a low dose TopIIa in-
hibitor with a EZH2 inhibitor is beneficial against ag-
gressive prostate cancer [75]. Likewise, EZH2 inhibition
sensitizes transcription activator BRG1 (ATP-dependent
helicase SMARCA4) and EGFR mutant lung tumors to
TopoII inhibitors, which suggest that combination therapy
is a promising approach to this cancer [76].
Novel epigenetic modulators continue to reach clinical
trials. For example, the first-in-man study of the toxicity,
pharmacokinetics, and pharmacodynamics of CG200745
46, a pan-HDAC inhibitor, in patients with refractory
solid malignancies was initiated in 2015 [77]. CG200745
46 can be safely administered at effective dose levels that
inhibit HDAC in peripheral blood mononuclear cells
(PBMCs) and tumor tissue, although maximum tolerated
dose (MTD) was not reached [77].
Combinations of epigenetic drugs
In the investigation of novel treatment options, the
simultaneous targeting of multiple epigenetic systems,
notably when HDACi and DNMTi are administered to-
gether, aims to achieve efficient epigenetic gene reacti-
vation (http://clinicaltrials.gov/). For example, results of
the phase I/II trial of combined epigenetic therapy with
DNMTi azacitidine 18 and HDACi entinostat 17 in ex-
tensively pretreated patients with recurrent metastatic
NSCL are encouraging [78]. The combination of vori-
nostat 1 and cladribine (2-chlorodeoxyadenosine) 47
de Lera and Ganesan Clinical Epigenetics  (2016) 8:105 Page 13 of 21synergistically induced apoptosis in natural killer cell
large granular lymphocytes (NK-LGL) leukemia [79].
Cladribine 47 is a drug approved for the treatment of
hairy-cell leukemia and acts as indirect DNMTi, since
it inhibits SAH hydrolase, increasing competition of
SAH for the SAM binding site.
The combination of HDACi (and also other chromatin
remodeling enzyme inhibitors such as DNMTi) with the
lysine methyltransferase inhibitor DZNep 43 revealed
the importance of pharmacological combinatorial ap-
proaches in breast cancer cells and in the regulation of
cancer immunity [80]. Also encouraging are the results
of triple combination using HDACi (TSA 48), DNMTi
(5-AZA-CdR, 19), and EZH2 inhibitor (DZNep, 43) on
human AML cells [81]. The triple combination (which
proved to be more effective than the combination of two
agents or a single agent) induced a remarkable synergis-
tic antineoplastic effect as demonstrated by an in vitro
colony assay and also showed a potent synergistic activa-
tion of several key tumor suppressor geners (TSGs) as
determined by real-time PCR.
The combination of vorinostat 1 and the LSD1 inhibi-
tor tranylcypromine 40 was able to reduce glioblastoma
stem cell viability and displayed efficacy in a U87 xeno-
graft model [82].
BET inhibitors are also promising therapeutic agents
[47, 49, 83], although resistance has been documented
[84, 85]. Their efficacy might be explained by the
chromosomal translocations involving bromodomains
BRD3 and BRD4 occurring in NUT midline carcinoma
(NMC) and in AML [86, 87]. BET inhibition led to
promising results in mouse models of sepsis [88], auto-
immunity (in combination with a Myc inhibitor) [89],
and inflammation of the lung [90]. As an example, JQ-1
49 [91] prevented tumor progression by promoting
differentiation in murine NMC [91] and also cardiac
hypertrophy in mice [92].
The combined inhibition of BET family proteins and
HDAC has been considered as a potential epigenetics-
based therapy for the treatment of pancreatic ductal
adenocarcinoma [93]. Clinical trials have also been initi-
ated for the treatment of relapsed or refractoryFig. 5 Selection of epigenetic drugs used in combination therapiesneuroblastoma (NCT02337309) and dose escalation stud-
ies for intravenous infusions in patients with other solid
cancers are underway (NCT00907205).
A combination of BET inhibitors (JQ-1 49) and SIRT
activators (SRT1720, 51) was found to alleviate inflam-
matory response due to the upregulation of SIRT1 by
the BETi JQ-1 49, thus reversing the pro-inflammatory
response to SIRT1 inhibition in a cellular lung disease
model [94]. On the other hand, the combination of JQ-1
49 with gamma-secretase inhibitors was shown to be ef-
fective against primary human leukemias in vivo [95].
The inhibition of SIRT1-mediated epigenetic silencing of
MLL-rearranged leukemia by disruptor of telomeric silen-
cing 1-like (DOT1L) inhibitors confirmed that the combin-
ation of epigenetic drugs (DOT1L inhibitor EPZ04777, 50
and SIRT1 activator SRT1720, 51) targeting the activation
and repression of gene expression is also a promising ap-
proach to treat leukemia [96] (Fig. 5).
Dual acting hybrids with an epigenetic and a second
mechanism of action
Epigenetic therapies are coming of age, and seven drugs
have been approved for cancer, with many more undergo-
ing clinical trials. Advances in genome-wide analyses and
bioinformatics are providing information on the disease-
supportive and disease-irrelevant gene networks that are
deregulated by aberrant epigenetic modifications. Features
important for epigenetic therapies are well recognized: (a)
epigenetic deregulation causes both gene specific and sys-
temic effects; (b) crosstalk and complex formation occur
between epigenetic modifiers, which implies that multiple
epigenetic systems are likely to be affected [97, 98]; (c)
genetic instability of cancer cells has the most likely al-
tered multiple epigenetic systems at the time a patient is
diagnosed; (d) the observations that existing epigenetic
drugs affect normal cells less than cancer cells indicated
either a higher epigenetic plasticity of normal cells or a
particular sensitivity of tumor cells to certain epigenetic
drug activities; (e) epigenetic drugs are in principle non-
genotoxic and their action can be made reversible upon
discontinuation of the treatment; (f) as for all drugs, the
development of resistance to a single agent is a concern;
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cognate target but also the silencing caused by other epi-
genetic enzymes [99].
Together, the above aspects provide a rationale for the
combination of pharmacophores, one of them targeting
the epigenetic enzymatic machinery, and also for the
simultaneous targeting of multiple epigenetic systems.
Most of the epigenetic drugs developed following the
first strategy are hybrid molecules containing the scaf-
fold of an HDACi fused/linked to another anticancer
drug, cytotoxic agent, anti-angiogenesis drug, etc., acting
at a related target. There are two principal reasons for
the popularity of HDACs in the design of dual targeting
agents. Firstly, HDACs are the epigenetic targets that
have received the most attention for drug discovery, and
consequently, there are a multitude of high affinity in-
hibitors known with diverse chemical scaffolds. Sec-
ondly, the HDAC pharmacophore, backed up by X-ray
cocrystal structures of enzyme-inhibitor complexes, in-
cludes a “cap” region that is protruding from the active
site channel and engaged in binding interactions with
the enzyme surface. While these are important, they are
less dominant in driving potency compared to the co-
ordination to the active site zinc cation. As a result, the
surface-binding cap is tolerant of a high degree of struc-
tural variation without compromising HDAC binding. It
is hence possible to incorporate a cap that contains the
pharmacophore for a second non-HDAC target and the
resulting chimeric molecule is capable of binding to
both these targets.
An early publication illustrating the multitarget principle
was reported by Pankiewic in 2007. Mycophenolic acid 52
(Fig. 6) is an inosine monophosphate dehydrogenase
(IMPDH) inhibitor clinically used as an immunosuppres-
sant that contains a carboxylic acid functional group. By
conversion to a hydroxamic acid, the analogue 53 was
demonstrated to retain nanomolar activity against IMPDH
while additionally acting as a micromolar HDAC inhibitorFig. 6 Examples of multitarget HDAC inhibitors obtained from drug molec[100]. The analogue was slightly more active (IC50 4.8 μM)
than mycophenolic acid in the growth inhibition of K562
cell lines. In the same way, other drugs containing car-
boxylic acids or their equivalents could be converted to
hydroxamic acids with the potential gain of HDAC in-
hibitory activity. Besides mycophenolic acid, another
example involves the blokcbuster drug lovastatin, a 3-
hydroxy-3-methylglutaryl coenzyme A reductase
(HMGCR) inhibitor used as a colesterol-lowering agent.
The corresponding lovastatin hydroxamic acid 54 was a
nanomolar inhibitor of both HMGCR and HDACs and
displayed efficacy in a colitis-associated colorectal can-
cer mouse model [101]. The authors additionally pre-
pared the hydroxamic acid versions 55 and 56 of
second-generation statins atorvastatin and rosuvastatin,
respectively. Both compounds were nanomolar inhibi-
tors of HDAC1, HDAC6, and HMGCR. In cell-based
assays, there was evidence of dual target engagement in
increased levels of acetylated histones and tubulin and
decreased enzymatic activity of HMGCR. Despite the
synthetic ease of taking known drugs containing car-
boxylic acids and converting them to hydroxamic acids,
this approach has rarely been employed as a means to
obtain HDACi gain of function in the resulting hybrid.
The most popular strategy for a dual action HDAC
inhibitor consists of taking a known pharmacophore for
a second target and grafting a side-chain containing a
spacer and a zinc-binding group. This has been exten-
sively studied with heterocyclic scaffolds that are protein
kinase inhibitors. Part of the rationale comes from the
synergy observed with kinase and HDAC inhibition
in vitro and in vivo models that has spurred clinical tri-
als featuring combination therapy as discussed above
(“Combinations of epigenetic drugs”). Furthermore, just
like HDAC inhibitors, kinase inhibitors often contain re-
gions that are involved in improving pharmacokinetics
rather than bonding interactions with the enzyme active
site and are amenable to modification. Since resistanceules containing carboxylic acids
Fig. 7 Dual HDAC and kinase inhibitors currently in clinical trials
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addition of an independent mechanism of action may
help circumvent this problem.
A number of approved kinase inhibitors have served
as an inspiration for the design of dual HDAC targeting
agents viz. erlotinib 26 [102, 103], imatinib 29 [104],
lapatinib [105], and vandetanib [106] as well as the clin-
ical candidate semaxanib [107]. The most advanced of
these hybrids, CUDC-101 57 (Fig. 7), from Curis, re-
cently completed phase I clinical trials in several forms
of cancer [108]. The Curis approach was based on the
X-ray cocrystal structure of erlotinib with EGFR that in-
dicates key hydrogen bond interactions between N1 and
N3 of the quinazoline heterocycle and the ATP binding
domain of the kinase. Meanwhile, the solvent exposed
phenoxy substitutents are protruding out of the active
site and not involved in significant enzyme binding. The
Curis scientists predicted that these positions should tol-
erate modification without loss of affinity and designed a
series of compounds containing a zinc-binding hydroxa-
mic acid and various spacers [109]. From this series,
CUDC-101 emerged as the clinical candidate. It is a
nanomolar inhibitor of the intended kinases (IC50 2 nM
for EGFR, 16 nM for HER2) while relatively inactive
against other kinases tested. In addition, it is a nanomo-
lar inhibitor of class I (IC50 HDAC1 4.5 nM, HDAC2
12.6 nM, HDAC3 9.1 nM, HDAC8 79.8 nM) and class II
HDACs (IC50 HDAC4 13.2 nM, HDAC5 11.4 nM,Fig. 8 PDE and topoisomerase inhibitors with dual HDAC inhibitory activityHDAC6 5.1 nM, HDAC7 373 nM, HDAC9 67.2 nM) as
well as HDAC10 (IC50 26.1 nM). The promising data
from phase I trials suggests that CUDC-101 will pro-
gress to phase II. In a separate program, Curis have ap-
plied the dual targeting philosophy to the non-protein
kinase, phosphatidylinositol 3-kinase (PI3K). In this case,
the pan-PI3K inhibitor pictilisib was the starting point
and led to the hybrid CUDC-907 58. The compound is
a nanomolar inhibitor of class I, II, and IV HDACs as
well as all four PI3K isoforms [110]. CUDC-907 is cur-
rently in phase II trials and has received orphan drug for
relapsed or refractory diffuse B cell lymphoma although
there may be concerns about toxicity as observed with
other pan-PI3K inhibitors.
The inhibition of enzymes that are not protein kinases
has also been succesfully combined with HDAC inhib-
ition. A patent [111] describes the preparation of hybrid
molecules based on the phosphodiesterase 5 (PDE5) in-
hibitor sildenafil (Viagra). The piperazine fragment in
sildenafil occupies a hydrophobic pocket in the enzyme
active site and can be altered without significant loss of
binding. Attachment of a hydroxamic acid led to dual
HDAC/PDE5 inhibitors exemplified by 59 (Fig. 8) that
inhibits HDACs and PDE5 with an IC50 below 10 nM.
In support of their application in Alzheimer’s disease,
these sildenafil hybrids increase acetylated tubulin levels
and decrease amyloid-β precursor protein and Tau phos-
phorylation, and cross the blood-brain barrier in a
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targeted are the DNA topoisomerases. A number of nat-
ural products including daunorubicin, camptothecin,
and podophyllotoxin are topoisomerase inhibitors that
are approved in their own right or led to semi-synthetic
derivatives in clinical use. These natural scaffolds have
been modified to attach a zinc-binding group, leading to
dual HDAC inhibition in preclinical examples such as
60 [112]. This compound was prepared in one step from
daunorubicin by reductive alkylation of the amine and
inhibited the DU-145 cell line with an IC50 of 1.6 μM. In
cell-based assays, HDAC inhibition was evidenced by in-
creased levels of p21 and acetylated H4 and tubulin,
while topoisomerase II inhibition was demonstrated in a
DNA plasmid relaxation assay and formation of the
trapped topoisomerase II-DNA cleavage complex at
micomolar drug concentrations.
Besides direct inhibition of enzymes, a different ap-
proach is the prevention of cellular localization to the
appropriate compartment. For example, the Ras GTPase
protein’s location in the cell membrane is inhibited by
the drug salirasib 61 (Fig. 9). The hydroxamic acid con-
taining conjugate 62 was a submicromolar inhibitor of
HDAC1, HDAC6, and HDAC8 [113]. In cells, the com-
pound increased acetylation levels of histones and tubu-
lin and decreased signaling through the phospho-protein
kinase B (pAkt) and phospho-protein kinase RNA-like
endoplasmatic reticulum kinase (pERK) pathways.
The above examples illustrate the dual action against
HDACs and a non-epigenetic enzyme. In the same way, it
is possible to design HDAC inhibitors that are ligands for a
non-epigenetic receptor. For example, the membrane pro-
tein smoothened is part of the Wnt/β-catenin signaling
pathway and is targeted by the recently approved antagonist
vismodegib. The hybrid molecule 63 is nanomolar in bind-
ing to the protein and inhibiting HDAC1, 2, 3 and 6 [114].
In cell-based assays, levels of acetylated histones andFig. 9 Protein receptor ligands with dual HDAC inhibitiontubulin was increased whereas Gli-2 and Hedgehog signal-
ing was decreased, supporting dual target engagement. A
number of ligands for the nuclear hormone superfamily
have been successfully modified to be dual HDAC inhibi-
tory agents. For example, 64 is a submicromolar inhibitor
of HDAC1 and the estrogen receptor and inhibited the
MCF7 cell line with an IC50 of 5 μM [115]. The level of ac-
tivity against HDACs is rather surprising as the compound
contains a carboxylic acid rather than the usual hydroxamic
acid as the zinc-binding group. Other groups have reported
ligands for the vitamin D [116] retinoid X [117] and andro-
gen [118] receptor that also inhibit HDACs.
Outside the field of enzymes and receptors, the cova-
lent alkylation of DNA has been combined with HDAC
inhibition. Compound 65 (Fig. 10) is an analogue of
the nitrogen mustard bendamustine that not only
causes DNA damage in cells but also inhibits HDAC1
and 6 at nanomolar levels and showed efficacy in a
HL60 xenograft model at a dose of 20 mg/kg [119].
Meanwhile, the natural product colchicine exerts an
anticancer effect through disruption of tubulin
polymerization. The colchicine analogue 66 inhibited
HDAC1 and tubulin polymerization at micromolar
levels and growth of the HCT116 cell line at a submi-
cromolar level [120].
Multitarget epigenetic modulators
While the above examples have all involved one epigen-
etic and one non-epigenetic mechanism of action, it is
possible to combine pharmacophores for multiple epi-
genetic targets in a single molecule. Two examples are
compounds 67 (Fig. 11) and 68 that were inspired by
the natural product scaffolds of curcumin and psamma-
plins respectively. Compound 67 affected histone methy-
lation, acetylation and deacetylation [121] while 68
inhibited HDAC1, DNMT, and SIRT1 at the tested con-
centration of 1 μM [122]. Meanwhile, elaboration of the
Fig. 10 Examples of DNA targeting HDAC inhibitors
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lase inhibition to the analogue 69 with a metal binding
motif accomplished additional inhibition of JmjC lysine
demethylases, thus effectively acting as an inhibitor of ly-
sine demethylation by both mechanisms of action [123].
At GlaxoSmithKline, a lead series for bromodomain
binding was modified to enable dual HDAC inhibition.
Compound 70 inhibited HDAC1 with an IC50 of 250 nM
and bound to BRD4 with a Kd of 50 nM and increased H4
acetylation levels and decreased c-myc levels in cells
[124]. However, the compound did not display synergy in
its action over the combination of single agent HDAC and
BRD inhibitors.
Finally, the purpose of dual targeting can be to en-
hance the effect upon the primary epigenetic mechanism
of action. The clinical candidate HDAC inhibitor entino-
stat 17 was conjugated to a NO donor to give 71
(Fig. 12). In this hybrid, inhibition of HDACs was ob-
served as well as an effect on cyclic GMP signaling and
an increase in the post-translational S-nitrosylation of
HDAC2 presumably due to the increased NO levelsFig. 11 Examples of dual epigenetic targeting compounds[125]. As discussed above, bromodomain ligands have
attracted much attention as potential therapeutic agents.
One issue, however, is that their effects can be transient
due to compensation by increased expression of the tar-
geted bromodomain. To overcome this problem, two
groups have recently conjugated JQ-1 49, a bromodo-
main tool compound with nanomolar affinity, to thalido-
mide, a drug used in the treatment of multiple myeloma.
Thalidomide acts by the recruitment of cereblon, a
cullin-dependent ubiquitin ligase that marks protein for
degradation by the proteasome. The hybrid compounds
72 and 73 hence bind to their bromodomain targets,
which then suffer cereblon induced protein degradation.
The cellular effects of the hybrids were shown to be more
potent and longer lasting than with JQ-1 [126, 127]. The
hybrid 73 showed efficacy in a mouse AML xenograft at
50 mg/kg.
Conclusions
Polypharmacology, rather than a highly specific “magic
bullet,” is the norm for small molecule drugs. A recent
Fig. 12 Compounds with a dual function to enhance an epigenetic mechanism of action
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cording to the Anatomical Therapeutic Chemical (ATC)
classification had a reported IC50 < 10 μM for six or
more targets [128]. While such promiscuity is usually
discovered serendipitiously, it can also be deliberately in-
corporated. In this review, we have described the two
major ways in which this has been achieved within the
relatively new area of epigenetic drug discovery. The first
is through combination therapy using two independent
and relatively selective drugs. At the present time, there
are ongoing clinical trials that are combining either an
epigenetic and a non-epigenetic drug or two epigenetic
drugs with distinct mechanisms of action. In many cases,
there is in vitro and in vivo evidence from animal
models that such combinations have a synergistic effect.
Furthermore, they may help widen the scope of epigen-
etic drugs beyond the narrow spectrum of hematological
cancers for which they are currently approved. The sec-
ond approach, which is more radical, involves the ra-
tional design of a new entity that exerts its biological
activity through two or more pathways. In epigenetics,
this has been highly successful with HDAC inhibitors
due to their simple and tolerant pharmacophore. The lit-
erature abounds with examples of multitarget HDAC in-
hibitors, and in two cases from the company Curis, both
linked with dual kinase inhibition, the compounds have
completed phase I clinical trials. As our understanding of
epigenetic targets and their biological relevance deepens,
further progress with epigenetic polypharmacology will
certainly be accomplished that directly benefits patients in
the clinic.
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